Sumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan

MT Newswires Live

Mar 02

Sumitomo Pharma Co (TYO:4506) unveiled "Boost 2028" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier "Reboot 2027" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.

The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.

Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.

The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616233610"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616233610\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616233610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616233610","market":"hk","top_or_hot":-1,"title":"Sumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SMDPY\">Sumitomo Pharma</a> Co (TYO:4506) unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.</p><p>Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.</p><p>The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-02 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SMDPY\">Sumitomo Pharma</a> Co (TYO:4506) unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.</p><p>Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.</p><p>The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROE","symbol_name":"ASTORIA US QUALITY KINGS ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616233610","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616233610","pubTimestamp":1772448296,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sumitomo Pharma Co  unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROE":"ASTORIA US QUALITY KINGS ETF"},"translate_title":"住友制药根据新的Boost 2028计划设定10%的ROE目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROE":1.5},"content_text":"Sumitomo Pharma Co (TYO:4506) unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}